Piper Sandler lowered the firm’s price target on Dentsply Sirona (XRAY) to $13 from $16 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results, with revenue finishing just ahead of Street but EBITDA and EPS missed. Guidance was cut across the board, and while in part a formality with investors already anticipating such a move, challenges in the U.S. are larger than originally thought, Piper adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona Unveils Strategic Plan Amid Q3 Losses
- DENTSPLY SIRONA Faces Challenges Amid Earnings Call Insights
- Dentsply Sirona downgraded to Market Perform from Outperform at William Blair
- DENTSPLY SIRONA: Hold Rating Amid Strategic Investments and Revised Growth Outlook
- Dentsply Sirona price target lowered to $13 from $15 at Stifel